Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE Study

被引:0
|
作者
Teixeira, Maria Margarida [1 ]
Dias, Joao [2 ]
Andre, Teresa [3 ]
Joaquim, Ana [4 ]
Fernandes, Ricardo [5 ]
Magalhaes, Joana [6 ]
Marreiros, Laura [7 ]
Pinto, Leonor [8 ]
Ribeiro, Leonor [9 ]
Nogueira, Mafalda [10 ]
Morais, Catarina [10 ]
机构
[1] Inst Portugues Oncol Coimbra Francisco Gentil, P-3000075 Coimbra, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, P-4200072 Porto, Portugal
[3] Hosp Dr Nelio Mendonca, P-9000177 Funchal, Portugal
[4] Unidade Local Saude Gaia Espinho, P-4434502 Vila Nova De Gaia, Portugal
[5] Unidade Local Saude Braga, P-4710243 Braga, Portugal
[6] Unidade Local Saude Algarve, P-8000386 Faro, Portugal
[7] Unidade Local Saude Almada Seixal, P-2805267 Almada, Portugal
[8] Unidade Local Saude Coimbra, P-3004561 Coimbra, Portugal
[9] Unidade Local Saude Santa Maria, P-1649035 Lisbon, Portugal
[10] MSD Portugal, Paco De Arcos, Portugal
关键词
head and neck; recurrent or metastatic disease; real-world; healthcare resources; patient management; SQUAMOUS-CELL CARCINOMA; GUIDELINES(R) INSIGHTS HEAD; RECURRENT/METASTATIC HEAD; PEMBROLIZUMAB; CHEMOTHERAPY; EPIDEMIOLOGY; KEYNOTE-048; CETUXIMAB; RISK;
D O I
10.3390/curroncol31080318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50-69 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (>70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.
引用
收藏
页码:4270 / 4283
页数:14
相关论文
共 50 条
  • [21] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
    Tencer, T.
    Xia, Q.
    Jobson, G.
    Qian, E.
    Dellon, E. S.
    VALUE IN HEALTH, 2022, 25 (07) : S432 - S432
  • [22] Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma
    Zhang, Ximei
    Wang, Peiguo
    Chai, Yanlan
    Zhou, Xuan
    Li, Ping
    Wang, Xudong
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2024, 45 (01)
  • [23] Real-world data of nivolumab efficacy for treatment of recurrent or metastatic head and neck squamous cell carcinoma
    Nosova, M. V.
    Stativko, O.
    Tsareva, E.
    Shangina, I.
    Ibragimova, M.
    Zueva, E.
    Latkin, V.
    Sobolev, M.
    Kuchevskaya, O.
    Arapova, O.
    Sabitov, E.
    Antonova, T.
    Pokataev, I.
    Galkin, V. N.
    ANNALS OF ONCOLOGY, 2024, 35
  • [24] Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data
    Patachi, Bogdana
    Jensen, Kristian H.
    Gothelf, Anita
    Bernsdorf, Mogens
    Friborg, Jeppe
    Kristensen, Claus A.
    ACTA ONCOLOGICA, 2025, 64 : 143 - 146
  • [25] HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany.
    Dietz, Andreas
    Welslau, Manfred
    Hahn, Dennis
    Langer, Christine
    Bockmuehl, Ulrike
    Mueller-Huesmann, Harald
    Busch, Chia-Jung
    Riera-Knorrenschild, Jorge
    Buentzel, Jens
    Kubuschok, Boris
    von der Gruen, Jens
    Gauler, Thomas Christoph
    Waldenberger, Daniela
    von der Heyde, Eyck
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Real-world outcomes for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab
    Singh, P.
    You, M.
    Lubinga, S.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] REAL-WORLD EVIDENCE ON HEALTHCARE RESOURCE USE AND ASSOCIATED COST WITH MULTIPLE MYELOMA IN THE NETHERLANDS
    Blommestein, H. M.
    Verelst, S. G.
    Zagorska, A.
    Stevanovic, J.
    Engstrom, A.
    Sonneveld, P.
    Huijgens, P. C.
    Lefevre, C.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2016, 19 (07) : A751 - A751
  • [28] Healthcare Resource Utilization and Cost of Care in Patients With Periocular Basal Cell Carcinoma: A Real-World Study
    Kahana, Alon
    Bartley, Karen
    Meyer, Craig S.
    Seetasith, Arpamas
    Lee, Janet
    McKenna, Edward
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 236 : 164 - 171
  • [29] HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF METASTATIC AND RECURRENT LOCALLY-ADVANCED HEAD AND NECK CANCER PATIENTS
    Le, T. K.
    Winfree, K. B.
    Yang, H.
    Marynchenko, M.
    Yu, A. P.
    Frois, C.
    Wu, E. Q.
    VALUE IN HEALTH, 2011, 14 (03) : A172 - A173
  • [30] Outcome of patients with recurrent/metastatic squamous cell head and neck cancer treated with platinum-based chemotherapy with or without cetuximab in real-world practice
    Zupancic, Tina
    Zakotnik, Branko
    Kuhar, Cvetka Grasic
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (03)